Last edition
News about Global Pharma
State of Texas Sues Bristol-Myers Squibb, Sanofi Over Alleged Failure to Disclose Plavix Efficacy
McKool Smith and The Lanier Law Firm, along with Texas Attorney General Ken Paxton, have filed a lawsuit on behalf of the State of Texas against Bristol-Myers Squibb Company and several Sanofi entities, alleging the companies failed to disclose the efficacy and safety profile of the drug Plavix, which is used as a blood thinner.
Global Pharma | 21/11/2025 | By Dineshwori | 154
Under this partnership, Antheia will leverage TAPI's next-generation fermentation capabilities and manufacturing facilities in Europe to further commercialise its pipeline of biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs).
Global Pharma | 21/11/2025 | By Dineshwori | 191
CPHI & PMEC India 2025 to Spotlight Global Pharma Innovation, Sustainability and Collaboration
Set to take place from 25–27 November 2025 at India Expo Mart, Greater Noida, Delhi, the 18th edition of CPHI & PMEC India 2025 will bring together over 2,000 exhibitors and 35,000 plus industry professionals.
Global Pharma | 18/11/2025 | By Dineshwori | 963
AstraZeneca and Sun Pharma have entered into a second exclusive brand partnership to expand access to Sodium Zirconium Cyclosilicate (SZC) in India for the management of Hyperkalaemia.
Global Pharma | 17/11/2025 | By Dineshwori | 676
Lupin Launches Risperidone Extended-Release Injectable with 180-day CGT Exclusivity in the US
Risperidone Long-Acting Injectable is Lupin’s first product using its proprietary PrecisionSphere technology developed by its subsidiary Nanomi.
Global Pharma | 14/11/2025 | By Dineshwori | 376
Uhlmann Pac-Systeme Opens New Branch in Jakarta to Establish Local Presence
Uhlmann Pac-Systeme, a global leader in pharmaceutical packaging systems, has further expanded its footprint in Southeast Asia with the opening of a new branch in Indonesia.
Global Pharma | 13/11/2025 | By Dineshwori | 395
Sandoz and EirGenix Ink Global Licensing Deal for Pertuzumab Biosimilar
Sandoz, the global leader in affordable medicines, has signed a global license agreement with Taiwanese biotech company EirGenix to commercialise a proposed biosimilar of the oncology medicine pertuzumab. The milestone-based deal, valued at up to USD 152 million, includes an upfront payment and potential market-based incentives.
Global Pharma | 13/11/2025 | By Dineshwori | 432
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and the Open Applications Group (OAGi) in the US have jointly unveiled a pioneering set of ontologies designed to enhance data interoperability and analytics capabilities across the biopharmaceutical industry.
Global Pharma | 13/11/2025 | By Dineshwori | 288
GSK Pharma to Procure Solar Power from CleanMax for its Plant at Nashik, Maharashtra
GlaxoSmithKline Pharmaceuticals (GSK Pharma) has approved a plan to procure 4.95 MWp of solar power for its Nashik plant from Clean Max Enviro Energy Solutions to increase the company’s renewable energy intake and cut down greenhouse gas emissions.
Global Pharma | 11/11/2025 | By Mrinmoy Dey | 441
Insilico Medicine and Eli Lilly Expand Collaboration to Accelerate AI-Driven Drug Discovery
The partnership aims to combine Insilico’s advanced Pharma.AI platforms with Lilly’s deep expertise in disease biology and drug development to jointly discover and advance innovative therapies for unmet medical needs.
Global Pharma | 11/11/2025 | By Dineshwori | 463
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy